PT141, PT-141 and bremelanotide can lead a reader into the same development programme. They can also lead to studies with different formulations, populations and outcomes. This reference explains how to connect those names without treating every result as a general sexual-performance claim or equating a research material with a finished medicine.
Follow the alias through a defined structure
Diamond and colleagues’ early clinical paper describes PT-141 as a cyclic heptapeptide melanocortin analogue. The PubMed substance record connects that name to bremelanotide.Diamond and colleagues — Placebo-controlled intranasal PT-141 evaluation (opens in a new tab)
The official Vyleesi description identifies bremelanotide acetate as a synthetic cyclic heptapeptide with an acetylated amino terminus and a free-acid carboxyl terminus. These chemical details are part of its identity, not optional additions to the name.DailyMed — Vyleesi description (opens in a new tab)
Novum’s supplied 10 mg report uses PT-141 and bremelanotide together and describes a lyophilised cyclic heptapeptide. It reports a reference match, but does not reproduce the full structural specification.Supplied PT-141 10 mg report (opens in a new tab)
Use the names together when searching, then check the actual material and formulation in each paper. A broad melanocortin label is not sufficient to substitute a related peptide’s results.
Keep earlier studies in their own clinical context
The 2004 Diamond study evaluated an intranasal preparation in healthy men and in men with erectile dysfunction who responded to sildenafil. It used an instrument-based erectile-response assessment and reported a response relative to placebo under its study conditions.Diamond and colleagues — Placebo-controlled intranasal PT-141 evaluation (opens in a new tab)
That is a specific population and endpoint. It should not be rewritten as a finding about every cause of erectile dysfunction, all sexual symptoms or an unrelated preparation.
A development programme can change formulation and clinical question over time. An earlier intranasal experiment does not define the exposure or performance of a later injectable product.
Read RECONNECT by its prespecified outcomes
Kingsberg and colleagues reported two phase 3 RECONNECT trials in premenopausal women with hypoactive sexual desire disorder. Across the trials, 1,267 women were randomised to bremelanotide or placebo for a 24-week treatment period.Kingsberg and colleagues — Two randomised phase 3 bremelanotide trials (opens in a new tab)
The coprimary outcomes concerned sexual desire and distress related to low desire. Both favoured bremelanotide statistically. Nausea, flushing and headache were more frequent with bremelanotide than with placebo.Kingsberg and colleagues — Two randomised phase 3 bremelanotide trials (opens in a new tab)
The report also distinguishes these findings from the count of satisfying sexual events associated with study drug, for which there was no significant between-group difference. A favourable desire score should not be presented as though every outcome improved.Kingsberg and colleagues — Two randomised phase 3 bremelanotide trials (opens in a new tab)
| Statement | What to retain |
|---|---|
| Desire improved | The specific desire measure and trial population |
| Distress decreased | Distress related to low desire, not all distress |
| An event outcome did not differ significantly | The result remains part of the account |
The evidence can be meaningful within its defined clinical question while remaining insufficient for a universal enhancement claim. The comparator and endpoint determine the conclusion, not the familiarity of the product name.
Separate molecule evidence from a supplied vial
Vyleesi’s official product description is for a formulated solution in an autoinjector. The supplied Novum report describes lyophilised research material. Those are different product descriptions even where the molecular name is shared.DailyMed — Vyleesi description (opens in a new tab)Supplied PT-141 10 mg report (opens in a new tab)
A certificate can document the tests reported for a sample. It does not establish that the sample was manufactured, formulated or clinically evaluated as the medicine in a trial.
When adding future studies, record whether they concern the same molecule, a changed formulation or a related melanocortin agent. Then identify the question answered before connecting the study to any product discussion.
This keeps the research history usable without turning clinical literature into an unsupported statement about the suitability or effects of a catalogue vial.
Sources and further detail
- Diamond and colleagues — Placebo-controlled intranasal PT-141 evaluation (opens in a new tab)
Original 2004 abstract and substance mapping read. Population, route and instrument-based endpoint retained; no administration instructions.
- DailyMed — Vyleesi description (opens in a new tab)
Official structural and formulated-product descriptions checked. Used to establish identity and product distinction, not UK availability or a use recommendation.
- Kingsberg and colleagues — Two randomised phase 3 bremelanotide trials (opens in a new tab)
Original abstract and indexed figure description read. Desire/distress findings, adverse observations and the non-significant satisfying-event comparison retained.
- Supplied PT-141 10 mg report (opens in a new tab)
Complete supplied PDF read. Lyophilised research-material identity statement distinguished from the clinical product; no independent authentication.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.